In Conversation

We have quite a significantly sized clinical trial team here in Hungary – even larger than our marketing team in fact

The most noticeable change [in the Hungarian healthcare landscape] is the speed of information sharing by companies and the amount available to the patients

AOP Orphan is a highly specialized company that truly caters to a niche segment of rare diseases.

As a parallel trade company, we must be compliant in the same manner as other pharma companies, and as a step between the original manufacturers and…

With the Falsified Medicines Directive of February 9, almost all drugs within the EU had to be serialized to curb the sale of counterfeit drugs.

MD Pál Szamosújvari, Judit Jávor, Pál Szamosújvari Jr—Founder, R&D Director, and Director of Pharma Patent respectively—share their insights on the activities of the company, the importance…

In comparison with Western European countries, Hungary has large state hospitals, which facilitates the conduct of clinical trials, while patients get access to treatments that are…

Hungary is actually one of the most fortunate countries in Europe for the treatment of diabetes. These products are well reimbursed, and patients have access to…

This new facility is currently one of the most modern healthcare infrastructures in Hungary, it will totally increase our efficiency and operational capacity

We grew more than 60 percent this year and the demand for our products has been booming

New technologies and trends are impacting the wholesaler value chain at an unprecedented pace

Our company's focus is on developing a dynamic pipeline to address unmet medical needs

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here